Navigation Links
Vical to Present at Upcoming Investor Conferences
Date:5/12/2008

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that Vical's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at three upcoming investor conferences:

* Bank of America 2008 Health Care Conference (Las Vegas, May 13 - 15),

* FBR Capital Markets 12th Annual Spring Investor Conference

(New York, May 28-29),

* Needham & Company Seventh Annual Biotechnology and Medical Technology

Conference.

A webcast of the presentation at the Needham conference will be available live and archived through the events page at http://www.vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and un
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vical Names Andrew de Guttadauro Vice President, Corporate Development
2. Vical to Present at Upcoming Investor Conferences
3. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
6. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
7. Vical to Present at Investor Conferences
8. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
9. Vical Presentation at Military Pandemic Influenza Workshop
10. Vical Launches Redesigned Website
11. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences Ltd. ... on the treatment of dementia, today announced that ... July 22 at 5:45 p.m. EDT following its ... Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , Chief ...
(Date:7/1/2015)... ... 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker provided ... , The presentation took place on Tuesday, June 16 and provided an update on ... for the treatment of pancreatic cancer. A copy of the company overview can ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... take part in the first half of “Integrative Biotechnology,” an applied biotechnology course ... in summer 2014, this course combines students from both universities and is taught ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... OpGen , a company that makes optical tests capable ... the final stage of its $5 million investment round. ... Wisconsin-Madison technology, already sells its testing services to a ... between marketing that service and new developments such as ...
... deep breath. Now say dis-intermediation. Remember that word? It was as ... today in certain vendor circles. The long and short of it ... guy and let suppliers sell directly to consumers, either in business ... slice of the middle-mans cut, suppliers would get better prices, and ...
... promote human embryonic stem-cell research, policymakers and investors will ask, ... is no. But among those states poised to compete with ... for success. , ,Thats because the $750 million proposal advanced ... research alone, but an interdisciplinary mix of sciences that may ...
Cached Biology Technology:OpGen completes $5 million investment round 2A funny thing happened on the way out of the back office 2A funny thing happened on the way out of the back office 3Life-science research plan is about more than stem cells 2Life-science research plan is about more than stem cells 3
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... among scientists, regulators, politicians, industry and the public ... possible harmful or adverse effects of nanoparticles on ... these incredibly small materials can behave quite differently ... products that promise benefits from these near-atomic level ...
... the Norwegians found one using a drill. The somewhat rough uncovering ... entire 2256 metres below the seabed. It had been there for ... wasn't a sea at all, but an enormous alluvial plane. , ... dinosaur now see the light of day again, or more precisely, ...
... Neanderthals is frequently attributed to competition from modern ... to make them more efficient as hunters. However, ... of Current Anthropology argues that the hunting practices ... indistinguishable, a conclusion leading to a different explanation, ...
Cached Biology News:New nano-canary in the nanotoxicology coalmine: The body itself 2
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
... Orange G Dye runs faster than ... standard agarose gels.,Orange G dye migrates ... long. The migration at this size,prevents ... and,conveniently indicates the front of DNA ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... without ammonium sulfate are compatible with thermostable ... Taq and AmpliThem™™ DNA polymerases. You can ... in one experiment by adding your own ... PreMixes supplied with the kit. This capability ...
Biology Products: